English
简体中文
Total: £ 56.28
Published Date: 2025-05-27 | Pages: 145 | Tables: 136 | Medical Care
In 2024, the global market size of RNAi for Therapeutic was estimated to be worth US$ 358 million and is forecast to reach approximately US$ 4272 million by 2031 with a CAGR of 43.1% during the forecast period 2025-2031.
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.
US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.
In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for RNAi for Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNAi for Therapeutic.
The RNAi for Therapeutic market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global RNAi for Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the RNAi for Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Segment by Type
siRNA
miRNA
shRNA
Segment by Application
Cancer
Cardiovascular
HBV
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of RNAi for Therapeutic in global and regional level.
Chapter 3: Detailed analysis of RNAi for Therapeutic company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, RNAi for Therapeutic revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 RNAi for Therapeutic Product Introduction
1.2 Market by Type
1.2.1 Global RNAi for Therapeutic Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 siRNA
1.2.3 miRNA
1.2.4 shRNA
1.3 Market by Application
1.3.1 Global RNAi for Therapeutic Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Cancer
1.3.3 Cardiovascular
1.3.4 HBV
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global RNAi for Therapeutic Market Size Estimates and Forecasts
2.2 RNAi for Therapeutic Market Size by Region: 2024 Versus 2031
2.2.1 Global RNAi for Therapeutic Revenue by Region: 2020-2025
2.2.2 Global RNAi for Therapeutic Revenue Forecast by Region (2026-2031)
2.2.3 Global RNAi for Therapeutic Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global RNAi for Therapeutic Revenue by Type (2020-2031)
3.1.2 Global RNAi for Therapeutic Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global RNAi for Therapeutic Revenue by Application (2020-2031)
3.2.2 Global RNAi for Therapeutic Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 siRNA of RNAi for Therapeutic Revenue Market Share by Application
3.3.2 miRNA of RNAi for Therapeutic Revenue Market Share by Application
3.3.3 shRNA of RNAi for Therapeutic Revenue Market Share by Application
4 Global RNAi for Therapeutic by Company
4.1 Global RNAi for Therapeutic Revenue by Company (2020-2025)
4.2 Global RNAi for Therapeutic Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key RNAi for Therapeutic Companies around the World: Ranking by Revenue
4.3.2 Global RNAi for Therapeutic Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global RNAi for Therapeutic Companies Headquarters & Product Type
4.4.1 Global RNAi for Therapeutic Companies Headquarters
4.4.2 Date of International Companies Enter into RNAi for Therapeutic Market
4.4.3 Global RNAi for Therapeutic Companies Product & Service
4.4.4 siRNA Revenue Market Share of RNAi for Therapeutic by Company
4.4.5 miRNA Revenue Market Share of RNAi for Therapeutic by Company
4.4.6 shRNA Revenue Market Share of RNAi for Therapeutic by Company
4.5 Global RNAi for Therapeutic Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Alnylam Pharmaceuticals
5.1.1 Alnylam Pharmaceuticals Corporation Information
5.1.2 Alnylam Pharmaceuticals Description, Business Overview
5.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Products Offered
5.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (2020-2025)
5.1.5 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue by Product in 2024
5.1.6 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue by Application in 2024
5.1.7 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue by Geographic Area in 2024
5.1.8 Alnylam Pharmaceuticals Recent Developments
5.2 Arbutus Biopharma (Tekmira)
5.2.1 Arbutus Biopharma (Tekmira) Corporation Information
5.2.2 Arbutus Biopharma (Tekmira) Description, Business Overview
5.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Products Offered
5.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue and Gross Margin (2020-2025)
5.2.5 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue by Product in 2024
5.2.6 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue by Application in 2024
5.2.7 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue by Geographic Area in 2024
5.2.8 Arbutus Biopharma (Tekmira) Recent Developments
5.3 Arrowhead
5.3.1 Arrowhead Corporation Information
5.3.2 Arrowhead Description, Business Overview
5.3.3 Arrowhead RNAi for Therapeutic Products Offered
5.3.4 Arrowhead RNAi for Therapeutic Revenue and Gross Margin (2020-2025)
5.3.5 Arrowhead RNAi for Therapeutic Revenue by Product in 2024
5.3.6 Arrowhead RNAi for Therapeutic Revenue by Application in 2024
5.3.7 Arrowhead RNAi for Therapeutic Revenue by Geographic Area in 2024
5.3.8 Arrowhead Recent Developments
5.4 Dicerna Pharmaceuticals
5.4.1 Dicerna Pharmaceuticals Corporation Information
5.4.2 Dicerna Pharmaceuticals Description, Business Overview
5.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Products Offered
5.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (2020-2025)
5.4.5 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue by Product in 2024
5.4.6 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue by Application in 2024
5.4.7 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue by Geographic Area in 2024
5.4.8 Dicerna Pharmaceuticals Recent Developments
5.5 Mirna Therapeutics
5.5.1 Mirna Therapeutics Corporation Information
5.5.2 Mirna Therapeutics Description, Business Overview
5.5.3 Mirna Therapeutics RNAi for Therapeutic Products Offered
5.5.4 Mirna Therapeutics RNAi for Therapeutic Revenue and Gross Margin (2020-2025)
5.5.5 Mirna Therapeutics RNAi for Therapeutic Revenue by Product in 2024
5.5.6 Mirna Therapeutics RNAi for Therapeutic Revenue by Application in 2024
5.5.7 Mirna Therapeutics RNAi for Therapeutic Revenue by Geographic Area in 2024
5.5.8 Mirna Therapeutics Recent Developments
5.6 Quark Pharmaceuticals
5.6.1 Quark Pharmaceuticals Corporation Information
5.6.2 Quark Pharmaceuticals Description, Business Overview
5.6.3 Quark Pharmaceuticals RNAi for Therapeutic Products Offered
5.6.4 Quark Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (2020-2025)
5.6.5 Quark Pharmaceuticals RNAi for Therapeutic Revenue by Product in 2024
5.6.6 Quark Pharmaceuticals RNAi for Therapeutic Revenue by Application in 2024
5.6.7 Quark Pharmaceuticals RNAi for Therapeutic Revenue by Geographic Area in 2024
5.6.8 Quark Pharmaceuticals Recent Developments
5.7 RXi Pharmaceuticals
5.7.1 RXi Pharmaceuticals Corporation Information
5.7.2 RXi Pharmaceuticals Description, Business Overview
5.7.3 RXi Pharmaceuticals RNAi for Therapeutic Products Offered
5.7.4 RXi Pharmaceuticals RNAi for Therapeutic Revenue and Gross Margin (2020-2025)
5.7.5 RXi Pharmaceuticals RNAi for Therapeutic Revenue by Product in 2024
5.7.6 RXi Pharmaceuticals RNAi for Therapeutic Revenue by Application in 2024
5.7.7 RXi Pharmaceuticals RNAi for Therapeutic Revenue by Geographic Area in 2024
5.7.8 RXi Pharmaceuticals Recent Developments
5.8 Silence Therapeutics
5.8.1 Silence Therapeutics Corporation Information
5.8.2 Silence Therapeutics Description, Business Overview
5.8.3 Silence Therapeutics RNAi for Therapeutic Products Offered
5.8.4 Silence Therapeutics RNAi for Therapeutic Revenue and Gross Margin (2020-2025)
5.8.5 Silence Therapeutics RNAi for Therapeutic Revenue by Product in 2024
5.8.6 Silence Therapeutics RNAi for Therapeutic Revenue by Application in 2024
5.8.7 Silence Therapeutics RNAi for Therapeutic Revenue by Geographic Area in 2024
5.8.8 Silence Therapeutics Recent Developments
5.9 Benitec Biopharma
5.9.1 Benitec Biopharma Corporation Information
5.9.2 Benitec Biopharma Description, Business Overview
5.9.3 Benitec Biopharma RNAi for Therapeutic Products Offered
5.9.4 Benitec Biopharma RNAi for Therapeutic Revenue and Gross Margin (2020-2025)
5.9.5 Benitec Biopharma RNAi for Therapeutic Revenue by Product in 2024
5.9.6 Benitec Biopharma RNAi for Therapeutic Revenue by Application in 2024
5.9.7 Benitec Biopharma RNAi for Therapeutic Revenue by Geographic Area in 2024
5.9.8 Benitec Biopharma Recent Developments
5.10 miRagen Therapeutics
5.10.1 miRagen Therapeutics Corporation Information
5.10.2 miRagen Therapeutics Description, Business Overview
5.10.3 miRagen Therapeutics RNAi for Therapeutic Products Offered
5.10.4 miRagen Therapeutics RNAi for Therapeutic Revenue and Gross Margin (2020-2025)
5.10.5 miRagen Therapeutics RNAi for Therapeutic Revenue by Product in 2024
5.10.6 miRagen Therapeutics RNAi for Therapeutic Revenue by Application in 2024
5.10.7 miRagen Therapeutics RNAi for Therapeutic Revenue by Geographic Area in 2024
5.10.8 miRagen Therapeutics Recent Developments
5.11 Sylentis
5.11.1 Sylentis Corporation Information
5.11.2 Sylentis Description, Business Overview
5.11.3 Sylentis RNAi for Therapeutic Products Offered
5.11.4 Sylentis RNAi for Therapeutic Revenue and Gross Margin (2020-2025)
5.11.5 Sylentis RNAi for Therapeutic Revenue by Product in 2024
5.11.6 Sylentis RNAi for Therapeutic Revenue by Application in 2024
5.11.7 Sylentis RNAi for Therapeutic Revenue by Geographic Area in 2024
5.11.8 Sylentis Recent Developments
5.12 Gradalis
5.12.1 Gradalis Corporation Information
5.12.2 Gradalis Description, Business Overview
5.12.3 Gradalis RNAi for Therapeutic Products Offered
5.12.4 Gradalis RNAi for Therapeutic Revenue and Gross Margin (2020-2025)
5.12.5 Gradalis RNAi for Therapeutic Revenue by Product in 2024
5.12.6 Gradalis RNAi for Therapeutic Revenue by Application in 2024
5.12.7 Gradalis RNAi for Therapeutic Revenue by Geographic Area in 2024
5.12.8 Gradalis Recent Developments
5.13 Sirnaomics
5.13.1 Sirnaomics Corporation Information
5.13.2 Sirnaomics Description, Business Overview
5.13.3 Sirnaomics RNAi for Therapeutic Products Offered
5.13.4 Sirnaomics RNAi for Therapeutic Revenue and Gross Margin (2020-2025)
5.13.5 Sirnaomics RNAi for Therapeutic Revenue by Product in 2024
5.13.6 Sirnaomics RNAi for Therapeutic Revenue by Application in 2024
5.13.7 Sirnaomics RNAi for Therapeutic Revenue by Geographic Area in 2024
5.13.8 Sirnaomics Recent Developments
5.14 Silenseed
5.14.1 Silenseed Corporation Information
5.14.2 Silenseed Description, Business Overview
5.14.3 Silenseed RNAi for Therapeutic Products Offered
5.14.4 Silenseed RNAi for Therapeutic Revenue and Gross Margin (2020-2025)
5.14.5 Silenseed RNAi for Therapeutic Revenue by Product in 2024
5.14.6 Silenseed RNAi for Therapeutic Revenue by Application in 2024
5.14.7 Silenseed RNAi for Therapeutic Revenue by Geographic Area in 2024
5.14.8 Silenseed Recent Developments
6 North America
6.1 North America RNAi for Therapeutic Market Size YoY Growth 2020-2031
6.2 North America RNAi for Therapeutic Market Facts & Figures by Country (2020-2031)
6.3 North America RNAi for Therapeutic Revenue by Type (2020-2025)
6.4 North America RNAi for Therapeutic Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific RNAi for Therapeutic Market Size YoY Growth 2020-2031
7.2 Asia-Pacific RNAi for Therapeutic Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific RNAi for Therapeutic Revenue by Type (2020-2025)
7.4 Asia-Pacific RNAi for Therapeutic Revenue by Application (2020-2025)
8 Europe
8.1 Europe RNAi for Therapeutic Market Size YoY Growth 2020-2031
8.2 Europe RNAi for Therapeutic Market Facts & Figures by Country (2020-2031)
8.3 Europe RNAi for Therapeutic Revenue by Type (2020-2025)
8.4 Europe RNAi for Therapeutic Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America RNAi for Therapeutic Market Size YoY Growth 2020-2031
9.2 Latin America RNAi for Therapeutic Market Facts & Figures by Country (2020-2031)
9.3 Latin America RNAi for Therapeutic Revenue by Type (2020-2025)
9.4 Latin America RNAi for Therapeutic Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America RNAi for Therapeutic Market Size YoY Growth 2020-2031
10.2 Middle East and Africa RNAi for Therapeutic Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa RNAi for Therapeutic Revenue by Type (2020-2025)
10.4 Middle East and Africa RNAi for Therapeutic Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 RNAi for Therapeutic Supply Chain Analysis
11.2 RNAi for Therapeutic Key Raw Materials and Upstream Suppliers
11.3 RNAi for Therapeutic Clients Analysis
11.4 RNAi for Therapeutic Sales Channel and Sales Model Analysis
11.4.1 RNAi for Therapeutic Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 RNAi for Therapeutic Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 RNAi for Therapeutic Distributors
12 RNAi for Therapeutic Market Dynamics
12.1 RNAi for Therapeutic Industry Trends
12.2 RNAi for Therapeutic Market Drivers
12.3 RNAi for Therapeutic Market Challenges
12.4 RNAi for Therapeutic Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global RNAi for Therapeutic Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global RNAi for Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global RNAi for Therapeutic Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global RNAi for Therapeutic Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global RNAi for Therapeutic Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global RNAi for Therapeutic Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global RNAi for Therapeutic Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global RNAi for Therapeutic Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global RNAi for Therapeutic Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. RNAi for Therapeutic Revenue by Company (2020-2025) & (US$ Million)
Table 11. RNAi for Therapeutic Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top RNAi for Therapeutic Players by Revenue (US$ Million) in 2024
Table 13. Global RNAi for Therapeutic Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global RNAi for Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2024)
Table 15. Global RNAi for Therapeutic Companies Headquarters
Table 16. Date of International Companies Enter into RNAi for Therapeutic Market
Table 17. Global RNAi for Therapeutic Companies Product & Service
Table 18. Global RNAi for Therapeutic Mergers & Acquisitions, Expansion Plans
Table 19. Alnylam Pharmaceuticals Corporation Information
Table 20. Alnylam Pharmaceuticals Description and Business Overview
Table 21. Alnylam Pharmaceuticals RNAi for Therapeutic Product
Table 22. Alnylam Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Alnylam Pharmaceuticals Revenue Proportion of RNAi for Therapeutic by Product in 2024
Table 24. Alnylam Pharmaceuticals Revenue Proportion of RNAi for Therapeutic by Application in 2024
Table 25. Alnylam Pharmaceuticals Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2024
Table 26. Alnylam Pharmaceuticals Recent Developments
Table 27. Arbutus Biopharma (Tekmira) Corporation Information
Table 28. Arbutus Biopharma (Tekmira) Description and Business Overview
Table 29. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product
Table 30. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. Arbutus Biopharma (Tekmira) Revenue Proportion of RNAi for Therapeutic by Product in 2024
Table 32. Arbutus Biopharma (Tekmira) Revenue Proportion of RNAi for Therapeutic by Application in 2024
Table 33. Arbutus Biopharma (Tekmira) Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2024
Table 34. Arbutus Biopharma (Tekmira) Recent Developments
Table 35. Arrowhead Corporation Information
Table 36. Arrowhead Description and Business Overview
Table 37. Arrowhead RNAi for Therapeutic Product
Table 38. Arrowhead RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Arrowhead Revenue Proportion of RNAi for Therapeutic by Product in 2024
Table 40. Arrowhead Revenue Proportion of RNAi for Therapeutic by Application in 2024
Table 41. Arrowhead Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2024
Table 42. Arrowhead Recent Developments
Table 43. Dicerna Pharmaceuticals Corporation Information
Table 44. Dicerna Pharmaceuticals Description and Business Overview
Table 45. Dicerna Pharmaceuticals RNAi for Therapeutic Product
Table 46. Dicerna Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Dicerna Pharmaceuticals Revenue Proportion of RNAi for Therapeutic by Product in 2024
Table 48. Dicerna Pharmaceuticals Revenue Proportion of RNAi for Therapeutic by Application in 2024
Table 49. Dicerna Pharmaceuticals Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2024
Table 50. Dicerna Pharmaceuticals Recent Developments
Table 51. Mirna Therapeutics Corporation Information
Table 52. Mirna Therapeutics Description and Business Overview
Table 53. Mirna Therapeutics RNAi for Therapeutic Product
Table 54. Mirna Therapeutics RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. Mirna Therapeutics Revenue Proportion of RNAi for Therapeutic by Product in 2024
Table 56. Mirna Therapeutics Revenue Proportion of RNAi for Therapeutic by Application in 2024
Table 57. Mirna Therapeutics Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2024
Table 58. Mirna Therapeutics Recent Developments
Table 59. Quark Pharmaceuticals Corporation Information
Table 60. Quark Pharmaceuticals Description and Business Overview
Table 61. Quark Pharmaceuticals RNAi for Therapeutic Product
Table 62. Quark Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. Quark Pharmaceuticals Revenue Proportion of RNAi for Therapeutic by Product in 2024
Table 64. Quark Pharmaceuticals Revenue Proportion of RNAi for Therapeutic by Application in 2024
Table 65. Quark Pharmaceuticals Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2024
Table 66. Quark Pharmaceuticals Recent Developments
Table 67. RXi Pharmaceuticals Corporation Information
Table 68. RXi Pharmaceuticals Description and Business Overview
Table 69. RXi Pharmaceuticals RNAi for Therapeutic Product
Table 70. RXi Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 71. RXi Pharmaceuticals Revenue Proportion of RNAi for Therapeutic by Product in 2024
Table 72. RXi Pharmaceuticals Revenue Proportion of RNAi for Therapeutic by Application in 2024
Table 73. RXi Pharmaceuticals Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2024
Table 74. RXi Pharmaceuticals Recent Developments
Table 75. Silence Therapeutics Corporation Information
Table 76. Silence Therapeutics Description and Business Overview
Table 77. Silence Therapeutics RNAi for Therapeutic Product
Table 78. Silence Therapeutics RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 79. Silence Therapeutics Revenue Proportion of RNAi for Therapeutic by Product in 2024
Table 80. Silence Therapeutics Revenue Proportion of RNAi for Therapeutic by Application in 2024
Table 81. Silence Therapeutics Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2024
Table 82. Silence Therapeutics Recent Developments
Table 83. Benitec Biopharma Corporation Information
Table 84. Benitec Biopharma Description and Business Overview
Table 85. Benitec Biopharma RNAi for Therapeutic Product
Table 86. Benitec Biopharma RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 87. Benitec Biopharma Revenue Proportion of RNAi for Therapeutic by Product in 2024
Table 88. Benitec Biopharma Revenue Proportion of RNAi for Therapeutic by Application in 2024
Table 89. Benitec Biopharma Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2024
Table 90. Benitec Biopharma Recent Developments
Table 91. miRagen Therapeutics Corporation Information
Table 92. miRagen Therapeutics Description and Business Overview
Table 93. miRagen Therapeutics RNAi for Therapeutic Product
Table 94. miRagen Therapeutics RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 95. miRagen Therapeutics Revenue Proportion of RNAi for Therapeutic by Product in 2024
Table 96. miRagen Therapeutics Revenue Proportion of RNAi for Therapeutic by Application in 2024
Table 97. miRagen Therapeutics Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2024
Table 98. miRagen Therapeutics Recent Developments
Table 99. Sylentis Corporation Information
Table 100. Sylentis Description and Business Overview
Table 101. Sylentis RNAi for Therapeutic Product
Table 102. Sylentis RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Sylentis Revenue Proportion of RNAi for Therapeutic by Product in 2024
Table 104. Sylentis Revenue Proportion of RNAi for Therapeutic by Application in 2024
Table 105. Sylentis Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2024
Table 106. Sylentis Recent Developments
Table 107. Gradalis Corporation Information
Table 108. Gradalis Description and Business Overview
Table 109. Gradalis RNAi for Therapeutic Product
Table 110. Gradalis RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 111. Gradalis Revenue Proportion of RNAi for Therapeutic by Product in 2024
Table 112. Gradalis Revenue Proportion of RNAi for Therapeutic by Application in 2024
Table 113. Gradalis Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2024
Table 114. Gradalis Recent Developments
Table 115. Sirnaomics Corporation Information
Table 116. Sirnaomics Description and Business Overview
Table 117. Sirnaomics RNAi for Therapeutic Product
Table 118. Sirnaomics RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 119. Sirnaomics Revenue Proportion of RNAi for Therapeutic by Product in 2024
Table 120. Sirnaomics Revenue Proportion of RNAi for Therapeutic by Application in 2024
Table 121. Sirnaomics Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2024
Table 122. Sirnaomics Recent Developments
Table 123. Silenseed Corporation Information
Table 124. Silenseed Description and Business Overview
Table 125. Silenseed RNAi for Therapeutic Product
Table 126. Silenseed RNAi for Therapeutic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 127. Silenseed Revenue Proportion of RNAi for Therapeutic by Product in 2024
Table 128. Silenseed Revenue Proportion of RNAi for Therapeutic by Application in 2024
Table 129. Silenseed Revenue Proportion of RNAi for Therapeutic by Geographic Area in 2024
Table 130. Silenseed Recent Developments
Table 131. North America RNAi for Therapeutic Revenue by Country (2020-2025) & (US$ Million)
Table 132. North America RNAi for Therapeutic Revenue by Country (2026-2031) & (US$ Million)
Table 133. North America RNAi for Therapeutic Revenue by Type (2020-2025) & (US$ Million)
Table 134. North America RNAi for Therapeutic Revenue by Application (2020-2025) & (US$ Million)
Table 135. Asia-Pacific RNAi for Therapeutic Revenue by Region (2020-2025) & (US$ Million)
Table 136. Asia-Pacific RNAi for Therapeutic Revenue by Region (2026-2031) & (US$ Million)
Table 137. Asia-Pacific RNAi for Therapeutic Revenue by Type (2020-2025) & (US$ Million)
Table 138. Asia-Pacific RNAi for Therapeutic Revenue by Application (2020-2025) & (US$ Million)
Table 139. Europe RNAi for Therapeutic Revenue by Country (2020-2025) & (US$ Million)
Table 140. Europe RNAi for Therapeutic Revenue by Country (2026-2031) & (US$ Million)
Table 141. Europe RNAi for Therapeutic Revenue by Type (2020-2025) & (US$ Million)
Table 142. Europe RNAi for Therapeutic Revenue by Application (2020-2025) & (US$ Million)
Table 143. Latin America RNAi for Therapeutic Revenue by Country (2020-2025) & (US$ Million)
Table 144. Latin America RNAi for Therapeutic Revenue by Country (2026-2031) & (US$ Million)
Table 145. Latin America RNAi for Therapeutic Revenue by Type (2020-2025) & (US$ Million)
Table 146. Latin America RNAi for Therapeutic Revenue by Application (2020-2025) & (US$ Million)
Table 147. Middle East and Africa RNAi for Therapeutic Revenue by Country (2020-2025) & (US$ Million)
Table 148. Middle East and Africa RNAi for Therapeutic Revenue by Country (2026-2031) & (US$ Million)
Table 149. Middle East and Africa RNAi for Therapeutic Revenue by Type (2020-2025) & (US$ Million)
Table 150. Middle East and Africa RNAi for Therapeutic Revenue by Application (2020-2025) & (US$ Million)
Table 151. RNAi for Therapeutic Key Raw Materials, Industry Status and Trend
Table 152. RNAi for Therapeutic Key Raw Materials and Upstream Suppliers
Table 153. RNAi for Therapeutic Clients Status and Trend
Table 154. RNAi for Therapeutic Typical Clients
Table 155. RNAi for Therapeutic Distributors
Table 156. RNAi for Therapeutic Market Trends
Table 157. RNAi for Therapeutic Market Drivers
Table 158. RNAi for Therapeutic Market Challenges
Table 159. RNAi for Therapeutic Market Restraints
Table 160. Research Programs/Design for This Report
Table 161. Key Data Information from Secondary Sources
Table 162. Key Data Information from Primary Sources
List of Figures
Figure 1. RNAi for Therapeutic Product Picture
Figure 2. Global RNAi for Therapeutic Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global RNAi for Therapeutic Revenue Market Share by Type in 2024 & 2031
Figure 4. siRNA Product Picture
Figure 5. miRNA Product Picture
Figure 6. shRNA Product Picture
Figure 7. Global RNAi for Therapeutic Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 8. Global RNAi for Therapeutic Revenue Market Share by Application in 2024 & 2031
Figure 9. Cancer
Figure 10. Cardiovascular
Figure 11. HBV
Figure 12. Others
Figure 13. RNAi for Therapeutic Report Years Considered
Figure 14. Global RNAi for Therapeutic Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global RNAi for Therapeutic Market Size (2020-2031) & (US$ Million)
Figure 16. Global RNAi for Therapeutic Market Size Market Share by Region: 2024 Versus 2031
Figure 17. Global RNAi for Therapeutic Revenue Market Share by Region (2020-2031)
Figure 18. Global RNAi for Therapeutic Revenue Market Share Forecast by Type (2020-2031)
Figure 19. Global RNAi for Therapeutic Revenue Market Share Forecast by Application (2020-2031)
Figure 20. siRNA of RNAi for Therapeutic Revenue Market Share by Application, 2024 VS 2031
Figure 21. miRNA of RNAi for Therapeutic Revenue Market Share by Application, 2024 VS 2031
Figure 22. shRNA of RNAi for Therapeutic Revenue Market Share by Application, 2024 VS 2031
Figure 23. RNAi for Therapeutic Revenue Share by Company (2024)
Figure 24. RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 25. siRNA Revenue Proportion by Company in 2024
Figure 26. miRNA Revenue Proportion by Company in 2024
Figure 27. shRNA Revenue Proportion by Company in 2024
Figure 28. North America RNAi for Therapeutic Revenue 2020-2031 (US$ Million)
Figure 29. North America RNAi for Therapeutic Revenue Market Share by Type (2020-2025)
Figure 30. North America RNAi for Therapeutic Revenue Market Share by Application (2020-2025)
Figure 31. Asia-Pacific RNAi for Therapeutic Revenue 2020-2031 (US$ Million)
Figure 32. Asia-Pacific RNAi for Therapeutic Revenue Market Share by Region (2020-2031)
Figure 33. Asia-Pacific RNAi for Therapeutic Revenue Market Share by Type (2020-2025)
Figure 34. Asia-Pacific RNAi for Therapeutic Revenue Market Share by Application (2020-2025)
Figure 35. Europe RNAi for Therapeutic Revenue Growth Rate 2020-2031 (US$ Million)
Figure 36. Europe RNAi for Therapeutic Revenue Market Share by Country (2020-2031)
Figure 37. Europe RNAi for Therapeutic Revenue Market Share by Type (2020-2025)
Figure 38. Europe RNAi for Therapeutic Revenue Market Share by Application (2020-2025)
Figure 39. Latin America RNAi for Therapeutic Revenue Growth Rate 2020-2031 (US$ Million)
Figure 40. Latin America RNAi for Therapeutic Revenue Market Share by Country (2020-2031)
Figure 41. Latin America RNAi for Therapeutic Revenue Market Share by Type (2020-2025)
Figure 42. Latin America RNAi for Therapeutic Revenue Market Share by Application (2020-2025)
Figure 43. Middle East and Africa RNAi for Therapeutic Revenue Growth Rate 2020-2031 (US$ Million)
Figure 44. Middle East and Africa RNAi for Therapeutic Revenue Market Share by Country (2020-2031)
Figure 45. Middle East and Africa RNAi for Therapeutic Revenue Market Share by Type (2020-2025)
Figure 46. Middle East and Africa RNAi for Therapeutic Revenue Market Share by Application (2020-2025)
Figure 47. RNAi for Therapeutic Supply Chain (Upstream and Downstream Market)
Figure 48. Global Production Market Share of RNAi for Therapeutic Raw Materials by Region in 2024
Figure 49. RNAi for Therapeutic Distribution Channels
Figure 50. Global RNAi for Therapeutic Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 51. Global RNAi for Therapeutic Percentage 2020-2031: Online Sales VS Offline Sales
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed
